Namjin Chung

Prior to joining Samsung Biologics in 2022, Dr. Chung had 28 years of experience in drug discovery and development in diverse R&D settings.

Since 2000, Dr. Chung has worked at MIT, Merck, BMS, Abbvie, UCSF, and Vesalius.

Dr. Chung has experience in CRISPR genome editing, functional genetics, human genetics, high-throughput screening, viral and non-viral delivery, iPSC models, and platform development for computational biology.

Dr. Chung is an accomplished drug discovery project leader in the areas of cancer, immunology, neurodegenerative, cardiovascular, metabolic, and infectious diseases through more than 20 program launches and transitions.

Dr. Chung received his PhD. and Master’s Degree from Duke University, and Bachelor’s Degree from Korea University.